{
    "abstract": "Introduction: Vascular endothelial growth factor (VEGF) is pivotal in tumor angiogenesis and therapies targeting the VEGF axis are widely used in the clinic for the treatment of cancer. We have developed a therapeutic vaccine targeting human (h)VEGF165. hVEGF26-104/RFASE is based on the truncated protein hVEGF26-104 as antigen formulated in an oil-in-water emulsion containing the sulpholipopolysaccharide RFASE as adjuvant. Here we describe the toxicity and immunogenicity of this therapeutic vaccine in cynomolgus monkeys. Methods: In total 54 cynomolgus monkeys were used and divided in 7 groups. Groups 1\u20133 were control groups, either receiving PBS alone (group 1), RFASE alone (group 2) or hVEGF26-104 alone (group 3). Animals allocated to groups 4\u20137 received hVEGF26-104 together with RFASE, but with varying doses of the antigen or the adjuvant. All animals were immunized four times with 2-week intervals and safety and immunogenicity were monitored until 3 days after the final immunization. Results: Immunization induced an RFASE adjuvant dependent acute phase response. High titers of antibodies against hVEGF26-104 and cross-reactive with hVEGF165, were found in monkey sera, 28 days after primer immunization. These antibodies were able to inhibit the binding of the monoclonal antibody bevacizumab with hVEGF165 in a competition ELISA. Moreover, the biological activity of hVEGF165 could be inhibited by the addition of immunized monkey serum in a VEGF specific bioassay. Importantly, no adverse events commonly observed with VEGF neutralization were observed throughout the study. Conclusion: These data show that hVEGF26-104/RFASE can be safely administered in cynomolgus monkeys, induces the desired immune response and therefore support the clinical development of this vaccine.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Herbert",
                    "initial": "H.",
                    "last": "Hurwitz"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fehrenbacher"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Novotny"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Cartwright"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Hainsworth"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Heim"
                },
                {
                    "first": "Jordan",
                    "initial": "J.",
                    "last": "Berlin"
                },
                {
                    "first": "Ari",
                    "initial": "A.",
                    "last": "Baron"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Griffing"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Holmgren"
                },
                {
                    "first": "Napoleone",
                    "initial": "N.",
                    "last": "Ferrara"
                },
                {
                    "first": "Gwen",
                    "initial": "G.",
                    "last": "Fyfe"
                },
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Rogers"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Ross"
                },
                {
                    "first": "Fairooz",
                    "initial": "F.",
                    "last": "Kabbinavar"
                }
            ],
            "doi": "10.1056/NEJMoa032691",
            "firstpage": "2335",
            "issn": "00284793",
            "lastpage": "2342",
            "pmid": "15175435",
            "pub_year": 2004,
            "title": "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer",
            "volume": "350"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Escudier"
                },
                {
                    "first": "Joaquim",
                    "initial": "J.",
                    "last": "Bellmunt"
                },
                {
                    "first": "Sylvie",
                    "initial": "S.",
                    "last": "N\u00e9grier"
                },
                {
                    "first": "Emilio",
                    "initial": "E.",
                    "last": "Bajetta"
                },
                {
                    "first": "Bohuslav",
                    "initial": "B.",
                    "last": "Melichar"
                },
                {
                    "first": "Sergio",
                    "initial": "S.",
                    "last": "Bracarda"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Ravaud"
                },
                {
                    "first": "Sophie",
                    "initial": "S.",
                    "last": "Golding"
                },
                {
                    "first": "Sangeeta",
                    "initial": "S.",
                    "last": "Jethwa"
                },
                {
                    "first": "Vesna",
                    "initial": "V.",
                    "last": "Sneller"
                }
            ],
            "doi": "10.1200/JCO.2009.26.7849",
            "firstpage": "2144",
            "issn": "0732183X",
            "lastpage": "2150",
            "pmid": "20368553",
            "pub_year": 2010,
            "title": "Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival",
            "volume": "28"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Van Cutsem"
                },
                {
                    "first": "Josep",
                    "initial": "J.",
                    "last": "Tabernero"
                },
                {
                    "first": "Radek",
                    "initial": "R.",
                    "last": "Lakomy"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "Prenen"
                },
                {
                    "first": "Jana",
                    "initial": "J.",
                    "last": "Prausov\u00e1"
                },
                {
                    "first": "Teresa",
                    "initial": "T.",
                    "last": "Macarulla"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Ruff"
                },
                {
                    "first": "Guy A.",
                    "initial": "G.A.",
                    "last": "Van Hazel"
                },
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "Moiseyenko"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Ferry"
                },
                {
                    "first": "Joe",
                    "initial": "J.",
                    "last": "McKendrick"
                },
                {
                    "first": "Jonathan",
                    "initial": "J.",
                    "last": "Polikoff"
                },
                {
                    "first": "Alexia",
                    "initial": "A.",
                    "last": "Tellier"
                },
                {
                    "first": "R\u00e9mi",
                    "initial": "R.",
                    "last": "Castan"
                },
                {
                    "first": "Carmen",
                    "initial": "C.",
                    "last": "Allegra"
                }
            ],
            "doi": "10.1200/JCO.2012.42.8201",
            "firstpage": "3499",
            "issn": "0732183X",
            "lastpage": "3506",
            "pmid": "22949147",
            "pub_year": 2012,
            "title": "Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen",
            "volume": "30"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Elisabeth J.M.",
                    "initial": "E.J.M.",
                    "last": "Huijbers"
                },
                {
                    "first": "Judy R.",
                    "initial": "J.R.",
                    "last": "Van Beijnum"
                },
                {
                    "first": "Victor L.",
                    "initial": "V.L.",
                    "last": "Thijssen"
                },
                {
                    "first": "Siamack",
                    "initial": "S.",
                    "last": "Sabrkhany"
                },
                {
                    "first": "Patrycja",
                    "initial": "P.",
                    "last": "Nowak-Sliwinska"
                },
                {
                    "first": "Arjan W.",
                    "initial": "A.W.",
                    "last": "Griffioen"
                }
            ],
            "doi": "10.1016/j.drup.2016.02.002",
            "firstpage": "26",
            "issn": "13687646",
            "lastpage": "37",
            "pmid": "27155374",
            "pub_year": 2016,
            "title": "Role of the tumor stroma in resistance to anti-angiogenic therapy",
            "volume": "25"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Jaafar",
                    "initial": "J.",
                    "last": "Bennouna"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Sastre"
                },
                {
                    "first": "Dirk",
                    "initial": "D.",
                    "last": "Arnold"
                },
                {
                    "first": "Pia",
                    "initial": "P.",
                    "last": "\u00d6sterlund"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Greil"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Van Cutsem"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "von Moos"
                },
                {
                    "first": "Jose Maria",
                    "initial": "J.M.",
                    "last": "Vi\u00e9itez"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Bouch\u00e9"
                },
                {
                    "first": "Christophe",
                    "initial": "C.",
                    "last": "Borg"
                },
                {
                    "first": "Claus Christoph",
                    "initial": "C.C.",
                    "last": "Steffens"
                },
                {
                    "first": "Vicente",
                    "initial": "V.",
                    "last": "Alonso-Ordu\u00f1a"
                },
                {
                    "first": "Christoph",
                    "initial": "C.",
                    "last": "Schlichting"
                },
                {
                    "first": "Irmarie",
                    "initial": "I.",
                    "last": "Reyes-Rivera"
                },
                {
                    "first": "Belguendouz",
                    "initial": "B.",
                    "last": "Bendahmane"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Andr\u00e9"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Kubicka"
                }
            ],
            "doi": "10.1016/S1470-2045(12)70477-1",
            "firstpage": "29",
            "issn": "14702045",
            "lastpage": "37",
            "pmid": "23168366",
            "pub_year": 2013,
            "title": "Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial",
            "volume": "14"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Gunter",
                    "initial": "G.",
                    "last": "von Minckwitz"
                },
                {
                    "first": "Fabio",
                    "initial": "F.",
                    "last": "Puglisi"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Cortes"
                },
                {
                    "first": "Eduard",
                    "initial": "E.",
                    "last": "Vrdoljak"
                },
                {
                    "first": "Norbert",
                    "initial": "N.",
                    "last": "Marschner"
                },
                {
                    "first": "Christoph",
                    "initial": "C.",
                    "last": "Zielinski"
                },
                {
                    "first": "Cristian",
                    "initial": "C.",
                    "last": "Villanueva"
                },
                {
                    "first": "Gilles",
                    "initial": "G.",
                    "last": "Romieu"
                },
                {
                    "first": "Istv\u00e1n",
                    "initial": "I.",
                    "last": "Lang"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Ciruelos"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "De Laurentiis"
                },
                {
                    "first": "Corinne",
                    "initial": "C.",
                    "last": "Veyret"
                },
                {
                    "first": "Sabine",
                    "initial": "S.",
                    "last": "de Ducla"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Freudensprung"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Srock"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Gligorov"
                }
            ],
            "doi": "10.1016/S1470-2045(14)70439-5",
            "firstpage": "1269",
            "issn": "14702045",
            "lastpage": "1278",
            "pmid": "25273342",
            "pub_year": 2014,
            "title": "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial",
            "volume": "15"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Gianluca",
                    "initial": "G.",
                    "last": "Masi"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Salvatore"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Boni"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Loupakis"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Cremolini"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Fornaro"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Schirripa"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Cupini"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Barbara"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Safina"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Granetto"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Fea"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Antonuzzo"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Boni"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Allegrini"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Chiara"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Amoroso"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Bonetti"
                }
            ],
            "doi": "10.1093/annonc/mdv012",
            "firstpage": "724",
            "issn": "09237534",
            "lastpage": "730",
            "pmid": "25600568",
            "pub_year": 2015,
            "title": "Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial",
            "volume": "26"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Judy R.",
                    "initial": "J.R.",
                    "last": "van Beijnum"
                },
                {
                    "first": "Patrycja",
                    "initial": "P.",
                    "last": "Nowak-Sliwinska"
                },
                {
                    "first": "Elisabeth J.M.",
                    "initial": "E.J.M.",
                    "last": "Huijbers"
                },
                {
                    "first": "Victor L.",
                    "initial": "V.L.",
                    "last": "Thijssen"
                },
                {
                    "first": "Arjan W.",
                    "initial": "A.W.",
                    "last": "Griffioen"
                }
            ],
            "doi": "10.1124/pr.114.010215",
            "firstpage": "441",
            "issn": "00316997",
            "lastpage": "461",
            "pmid": "25769965",
            "pub_year": 2015,
            "title": "The great escape; the hallmarks of resistance to antiangiogenic therapy",
            "volume": "67"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Anil",
                    "initial": "A.",
                    "last": "Bagri"
                },
                {
                    "first": "Leanne",
                    "initial": "L.",
                    "last": "Berry"
                },
                {
                    "first": "Bert",
                    "initial": "B.",
                    "last": "Gunter"
                },
                {
                    "first": "Mallika",
                    "initial": "M.",
                    "last": "Singh"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Kasman"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Damico"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Xiang"
                },
                {
                    "first": "Maike",
                    "initial": "M.",
                    "last": "Schmidt"
                },
                {
                    "first": "Germaine",
                    "initial": "G.",
                    "last": "Fuh"
                },
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Hollister"
                },
                {
                    "first": "Oliver",
                    "initial": "O.",
                    "last": "Rosen"
                },
                {
                    "first": "Greg D.",
                    "initial": "G.D.",
                    "last": "Plowman"
                }
            ],
            "doi": "10.1158/1078-0432.CCR-09-3100",
            "firstpage": "3887",
            "issn": "10780432",
            "lastpage": "3900",
            "pmid": "20554752",
            "pub_year": 2010,
            "title": "Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy",
            "volume": "16"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Madelon Q.",
                    "initial": "M.Q.",
                    "last": "Wentink"
                },
                {
                    "first": "Elisabeth J.M.",
                    "initial": "E.J.M.",
                    "last": "Huijbers"
                },
                {
                    "first": "Tanja D.",
                    "initial": "T.D.",
                    "last": "de Gruijl"
                },
                {
                    "first": "Henk M.W.",
                    "initial": "H.M.W.",
                    "last": "Verheul"
                },
                {
                    "first": "Anna Karin",
                    "initial": "A.K.",
                    "last": "Olsson"
                },
                {
                    "first": "Arjan W.",
                    "initial": "A.W.",
                    "last": "Griffioen"
                }
            ],
            "doi": "10.1016/j.bbcan.2015.01.005",
            "firstpage": "155",
            "issn": "0304419X",
            "lastpage": "171",
            "pmid": "25641676",
            "pub_year": 2015,
            "title": "Vaccination approach to anti-angiogenic treatment of cancer",
            "volume": "1855"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Debra",
                    "initial": "D.",
                    "last": "Kamstock"
                },
                {
                    "first": "Robyn",
                    "initial": "R.",
                    "last": "Elmslie"
                },
                {
                    "first": "Douglas",
                    "initial": "D.",
                    "last": "Thamm"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Dow"
                }
            ],
            "doi": "10.1007/s00262-007-0282-7",
            "firstpage": "1299",
            "issn": "03407004",
            "lastpage": "1309",
            "pmid": "17502972",
            "pub_year": 2007,
            "title": "Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma",
            "volume": "56"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Yu Quan",
                    "initial": "Y.Q.",
                    "last": "Wei"
                },
                {
                    "first": "Mei Juan",
                    "initial": "M.J.",
                    "last": "Huang"
                },
                {
                    "first": "Li",
                    "initial": "L.",
                    "last": "Yang"
                },
                {
                    "first": "Xia",
                    "initial": "X.",
                    "last": "Zhao"
                },
                {
                    "first": "Ling",
                    "initial": "L.",
                    "last": "Tian"
                },
                {
                    "first": "You",
                    "initial": "Y.",
                    "last": "Lu"
                },
                {
                    "first": "Jing Mei",
                    "initial": "J.M.",
                    "last": "Shu"
                },
                {
                    "first": "Chong Jiu",
                    "initial": "C.J.",
                    "last": "Lu"
                },
                {
                    "first": "Ting",
                    "initial": "T.",
                    "last": "Niu"
                },
                {
                    "first": "Bin",
                    "initial": "B.",
                    "last": "Kang"
                },
                {
                    "first": "Yun Qiu",
                    "initial": "Y.Q.",
                    "last": "Mao"
                },
                {
                    "first": "Fen",
                    "initial": "F.",
                    "last": "Liu"
                },
                {
                    "first": "Yan Jun",
                    "initial": "Y.J.",
                    "last": "Wen"
                },
                {
                    "first": "Shong",
                    "initial": "S.",
                    "last": "Lei"
                },
                {
                    "first": "Feng",
                    "initial": "F.",
                    "last": "Luo"
                },
                {
                    "first": "Li Qun",
                    "initial": "L.Q.",
                    "last": "Zhou"
                },
                {
                    "first": "Feng",
                    "initial": "F.",
                    "last": "Peng"
                },
                {
                    "first": "Yu",
                    "initial": "Y.",
                    "last": "Jiang"
                },
                {
                    "first": "Ji Yan",
                    "initial": "J.Y.",
                    "last": "Liu"
                },
                {
                    "first": "Hao",
                    "initial": "H.",
                    "last": "Zhou"
                },
                {
                    "first": "Qing Ru",
                    "initial": "Q.R.",
                    "last": "Wang"
                },
                {
                    "first": "Qiu Ming",
                    "initial": "Q.M.",
                    "last": "He"
                },
                {
                    "first": "Fei",
                    "initial": "F.",
                    "last": "Xiao"
                },
                {
                    "first": "Yan Yan",
                    "initial": "Y.Y.",
                    "last": "Lou"
                },
                {
                    "first": "Xing Jiang",
                    "initial": "X.J.",
                    "last": "Xie"
                },
                {
                    "first": "Qiu",
                    "initial": "Q.",
                    "last": "Li"
                },
                {
                    "first": "Yang",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "Zhen Yu",
                    "initial": "Z.Y.",
                    "last": "Ding"
                },
                {
                    "first": "Bin",
                    "initial": "B.",
                    "last": "Hu"
                },
                {
                    "first": "Min",
                    "initial": "M.",
                    "last": "Hu"
                },
                {
                    "first": "Wei",
                    "initial": "W.",
                    "last": "Zhang"
                }
            ],
            "doi": "10.1073/pnas.191112198",
            "firstpage": "11545",
            "issn": "00278424",
            "lastpage": "11550",
            "pmid": "11553767",
            "pub_year": 2001,
            "title": "Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen",
            "volume": "98"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Farhad Haghighi",
                    "initial": "F.H.",
                    "last": "Rad"
                },
                {
                    "first": "H\u00e9l\u00e8ne",
                    "initial": "H.",
                    "last": "Le Buanec"
                },
                {
                    "first": "S\u00e9bastien",
                    "initial": "S.",
                    "last": "Paturance"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Larcier"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Genne"
                },
                {
                    "first": "Bernhard",
                    "initial": "B.",
                    "last": "Ryffel"
                },
                {
                    "first": "Armand",
                    "initial": "A.",
                    "last": "Bensussan"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Bizzini"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Gallo"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Zagury"
                },
                {
                    "first": "Georges",
                    "initial": "G.",
                    "last": "Uzan"
                }
            ],
            "doi": "10.1073/pnas.0611022104",
            "firstpage": "2837",
            "issn": "00278424",
            "lastpage": "2842",
            "pmid": "17301234",
            "pub_year": 2007,
            "title": "VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases",
            "volume": "104"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Madelon Q.",
                    "initial": "M.Q.",
                    "last": "Wentink"
                },
                {
                    "first": "Tilman M.",
                    "initial": "T.M.",
                    "last": "Hackeng"
                },
                {
                    "first": "Sebastien P.",
                    "initial": "S.P.",
                    "last": "Tabruyn"
                },
                {
                    "first": "Wouter C.",
                    "initial": "W.C.",
                    "last": "Puijk"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Schwamborn"
                },
                {
                    "first": "Daniele",
                    "initial": "D.",
                    "last": "Altschuh"
                },
                {
                    "first": "Rob H.",
                    "initial": "R.H.",
                    "last": "Meloen"
                },
                {
                    "first": "Teun",
                    "initial": "T.",
                    "last": "Schuurman"
                },
                {
                    "first": "Arjan W.",
                    "initial": "A.W.",
                    "last": "Griffioen"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Timmerman"
                }
            ],
            "doi": "10.1073/pnas.1610258113",
            "firstpage": "12532",
            "issn": "00278424",
            "lastpage": "12537",
            "pmid": "27791128",
            "pub_year": 2016,
            "title": "Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity",
            "volume": "113"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Yanelys",
                    "initial": "Y.",
                    "last": "Morera"
                },
                {
                    "first": "M\u00f3nica",
                    "initial": "M.",
                    "last": "Bequet-Romero"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Ayala"
                },
                {
                    "first": "Jorge Castro",
                    "initial": "J.C.",
                    "last": "Velazco"
                },
                {
                    "first": "Pedro Puente",
                    "initial": "P.P.",
                    "last": "P\u00e9rez"
                },
                {
                    "first": "Jes\u00fas Su\u00e1rez",
                    "initial": "J.S.",
                    "last": "Alba"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Ancizar"
                },
                {
                    "first": "Meilyn",
                    "initial": "M.",
                    "last": "Rodr\u00edguez"
                },
                {
                    "first": "Karelia",
                    "initial": "K.",
                    "last": "Cosme"
                },
                {
                    "first": "Jorge V.",
                    "initial": "J.V.",
                    "last": "Gavilondo"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.02.069",
            "firstpage": "3453",
            "issn": "0264410X",
            "lastpage": "3461",
            "pmid": "20197134",
            "pub_year": 2010,
            "title": "Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates",
            "volume": "28"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Yanelys",
                    "initial": "Y.",
                    "last": "Morera"
                },
                {
                    "first": "M\u00f3nica",
                    "initial": "M.",
                    "last": "Bequet-Romero"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Ayala"
                },
                {
                    "first": "Pedro Puente",
                    "initial": "P.P.",
                    "last": "P\u00e9rez"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Castro"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "S\u00e1nchez"
                },
                {
                    "first": "Jos\u00e9 Su\u00e1rez",
                    "initial": "J.S.",
                    "last": "Alba"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Anc\u00edzar"
                },
                {
                    "first": "Karelia",
                    "initial": "K.",
                    "last": "Cosme"
                },
                {
                    "first": "Jorge V.",
                    "initial": "J.V.",
                    "last": "Gavilondo"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.10.082",
            "firstpage": "368",
            "issn": "0264410X",
            "lastpage": "377",
            "pmid": "22075086",
            "pub_year": 2012,
            "title": "Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates",
            "volume": "30"
        },
        "b0085": {
            "authors": [
                {
                    "first": "J. V.",
                    "initial": "J.V.",
                    "last": "Gavilondo"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Hern\u00e1ndez-Bernal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ayala-\u00c1vila"
                },
                {
                    "first": "A. V.",
                    "initial": "A.V.",
                    "last": "de la Torre"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "de la Torre"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Morera-D\u00edaz"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Bequet-Romero"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "S\u00e1nchez"
                },
                {
                    "first": "C. M.",
                    "initial": "C.M.",
                    "last": "Valenzuela"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Mart\u00edn"
                },
                {
                    "first": "K. H.",
                    "initial": "K.H.",
                    "last": "Selman-Housein"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Garabito"
                },
                {
                    "first": "O. C.",
                    "initial": "O.C.",
                    "last": "Lazo"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.11.102",
            "firstpage": "2241",
            "issn": "0264410X",
            "lastpage": "2250",
            "pmid": "24530151",
            "pub_year": 2014,
            "title": "Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial",
            "volume": "32"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Yanelys",
                    "initial": "Y.",
                    "last": "Morera"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "S\u00e1nchez"
                },
                {
                    "first": "M\u00f3nica",
                    "initial": "M.",
                    "last": "Bequet-Romero"
                },
                {
                    "first": "Katty Hind",
                    "initial": "K.H.",
                    "last": "Selman-Housein"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "de la Torre"
                },
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Hern\u00e1ndez-Bernal"
                },
                {
                    "first": "Yenima",
                    "initial": "Y.",
                    "last": "Mart\u00edn"
                },
                {
                    "first": "Acralys",
                    "initial": "A.",
                    "last": "Garabito"
                },
                {
                    "first": "Jes\u00fas",
                    "initial": "J.",
                    "last": "Pi\u00f1ero"
                },
                {
                    "first": "Cimara",
                    "initial": "C.",
                    "last": "Berm\u00fadez"
                },
                {
                    "first": "Josu\u00e9",
                    "initial": "J.",
                    "last": "de la Torre"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Ayala"
                },
                {
                    "first": "Jorge V.",
                    "initial": "J.V.",
                    "last": "Gavilondo"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.05.020",
            "firstpage": "3582",
            "issn": "0264410X",
            "lastpage": "3590",
            "pmid": "28536029",
            "pub_year": 2017,
            "title": "Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine",
            "volume": "35"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "S\u00e1nchez Ram\u00edrez"
                },
                {
                    "first": "Yanelys",
                    "initial": "Y.",
                    "last": "Morera D\u00edaz"
                },
                {
                    "first": "M\u00f3nica",
                    "initial": "M.",
                    "last": "Bequet-Romero"
                },
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Hern\u00e1ndez-Bernal"
                },
                {
                    "first": "Katty Hind",
                    "initial": "K.H.",
                    "last": "Selman-Housein Bernal"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "de la Torre Santos"
                },
                {
                    "first": "Eduardo Rafael",
                    "initial": "E.R.",
                    "last": "Santiesteban \u00c1lvarez"
                },
                {
                    "first": "Yenima",
                    "initial": "Y.",
                    "last": "Mart\u00edn Bauta"
                },
                {
                    "first": "Cimara H.",
                    "initial": "C.H.",
                    "last": "Berm\u00fadez Badell"
                },
                {
                    "first": "Josu\u00e9",
                    "initial": "J.",
                    "last": "de la Torre Pupo"
                },
                {
                    "first": "Jorge V.",
                    "initial": "J.V.",
                    "last": "Gavilondo"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Ayala Avila"
                },
                {
                    "first": "Mariela P\u00e9rez",
                    "initial": "M.P.",
                    "last": "de la Iglesia"
                },
                {
                    "first": "Sheila Padr\u00f3n",
                    "initial": "S.P.",
                    "last": "Morales"
                },
                {
                    "first": "Lian Trimi\u00f1o",
                    "initial": "L.T.",
                    "last": "Lorenzo"
                },
                {
                    "first": "Gerardo R.",
                    "initial": "G.R.",
                    "last": "Hern\u00e1ndez Gonz\u00e1lez"
                },
                {
                    "first": "Yasmiana",
                    "initial": "Y.",
                    "last": "Mu\u00f1oz Pozo"
                },
                {
                    "first": "Eduardo Iba\u00f1ez",
                    "initial": "E.I.",
                    "last": "Carrillo"
                },
                {
                    "first": "Rodolfo A.",
                    "initial": "R.A.",
                    "last": "Morales Yera"
                },
                {
                    "first": "Jes\u00fas Pi\u00f1ero",
                    "initial": "J.P.",
                    "last": "Molin\u00e9r"
                },
                {
                    "first": "Kirenia Camacho",
                    "initial": "K.C.",
                    "last": "Sosa"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1186/s12865-017-0222-z",
            "issn": "14712172",
            "pmid": "28747172",
            "pub_year": 2017,
            "title": "Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants",
            "volume": "18"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Castro"
                },
                {
                    "first": "Pedro",
                    "initial": "P.",
                    "last": "Puente"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Mart\u00ednez"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Hern\u00e1ndez"
                },
                {
                    "first": "Yanelys",
                    "initial": "Y.",
                    "last": "Morera"
                },
                {
                    "first": "Leticia",
                    "initial": "L.",
                    "last": "Mart\u00ednez"
                },
                {
                    "first": "Lizet",
                    "initial": "L.",
                    "last": "Aldana"
                },
                {
                    "first": "Iris",
                    "initial": "I.",
                    "last": "Vald\u00e9s"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Ayala"
                },
                {
                    "first": "Karelia",
                    "initial": "K.",
                    "last": "Cosme"
                }
            ],
            "doi": "10.1016/j.intimp.2017.04.023",
            "firstpage": "55",
            "issn": "15675769",
            "lastpage": "60",
            "pmid": "28463787",
            "pub_year": 2017,
            "title": "Vaccine CIGB 247 is potentially safe for use as a novel therapeutic vaccine against cancer in Chlorocebus aethiops monkeys",
            "volume": "48"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Germaine",
                    "initial": "G.",
                    "last": "Fuh"
                },
                {
                    "first": "Bing",
                    "initial": "B.",
                    "last": "Li"
                },
                {
                    "first": "Craig",
                    "initial": "C.",
                    "last": "Crowley"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Cunningham"
                },
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "Wells"
                }
            ],
            "doi": "10.1074/jbc.273.18.11197",
            "firstpage": "11197",
            "issn": "00219258",
            "lastpage": "11204",
            "pmid": "9556609",
            "pub_year": 1998,
            "title": "Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor",
            "volume": "273"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Kalyaneswar",
                    "initial": "K.",
                    "last": "Mandal"
                },
                {
                    "first": "Stephen B.H.",
                    "initial": "S.B.H.",
                    "last": "Kent"
                }
            ],
            "doi": "10.1002/anie.201103237",
            "firstpage": "8029",
            "issn": "14337851",
            "lastpage": "8033",
            "pmid": "21744452",
            "pub_year": 2011,
            "title": "Total chemical synthesis of biologically active vascular endothelial growth factor",
            "volume": "50"
        },
        "b0115": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Bodewes"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Geelhoed-Mieras"
                },
                {
                    "first": "J. G.M.",
                    "initial": "J.G.M.",
                    "last": "Heldens"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Glover"
                },
                {
                    "first": "B. N.",
                    "initial": "B.N.",
                    "last": "Lambrecht"
                },
                {
                    "first": "R. A.M.",
                    "initial": "R.A.M.",
                    "last": "Fouchier"
                },
                {
                    "first": "A. D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                },
                {
                    "first": "G. F.",
                    "initial": "G.F.",
                    "last": "Rimmelzwaan"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.09.015",
            "firstpage": "6833",
            "issn": "0264410X",
            "lastpage": "6839",
            "pmid": "19772942",
            "pub_year": 2009,
            "title": "The novel adjuvant CoVaccineHT\u2122 increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro",
            "volume": "27"
        },
        "b0120": null,
        "b0125": {
            "authors": [
                {
                    "first": "Taija",
                    "initial": "T.",
                    "last": "M\u00e4kinen"
                },
                {
                    "first": "Tanja",
                    "initial": "T.",
                    "last": "Veikkola"
                },
                {
                    "first": "Satu",
                    "initial": "S.",
                    "last": "Mustjoki"
                },
                {
                    "first": "Terhi",
                    "initial": "T.",
                    "last": "Karpanen"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Catimel"
                },
                {
                    "first": "Edouard C.",
                    "initial": "E.C.",
                    "last": "Nice"
                },
                {
                    "first": "Lyn",
                    "initial": "L.",
                    "last": "Wise"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Mercer"
                },
                {
                    "first": "Heinrich",
                    "initial": "H.",
                    "last": "Kowalski"
                },
                {
                    "first": "Dontscho",
                    "initial": "D.",
                    "last": "Kerjaschki"
                },
                {
                    "first": "Steven A.",
                    "initial": "S.A.",
                    "last": "Stacker"
                },
                {
                    "first": "Marc G.",
                    "initial": "M.G.",
                    "last": "Achen"
                },
                {
                    "first": "Kari",
                    "initial": "K.",
                    "last": "Alitalo"
                }
            ],
            "doi": "10.1093/emboj/20.17.4762",
            "firstpage": "4762",
            "issn": "02614189",
            "lastpage": "4773",
            "pmid": "11532940",
            "pub_year": 2001,
            "title": "Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3",
            "volume": "20"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Steven A.",
                    "initial": "S.A.",
                    "last": "Stacker"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Vitali"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Caesar"
                },
                {
                    "first": "Teresa",
                    "initial": "T.",
                    "last": "Domagala"
                },
                {
                    "first": "Leo C.",
                    "initial": "L.C.",
                    "last": "Groenen"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Nice"
                },
                {
                    "first": "Marc G.",
                    "initial": "M.G.",
                    "last": "Achen"
                },
                {
                    "first": "Andrew F.",
                    "initial": "A.F.",
                    "last": "Wilks"
                }
            ],
            "doi": "10.1074/jbc.274.49.34884",
            "firstpage": "34884",
            "issn": "00219258",
            "lastpage": "34892",
            "pmid": "10574962",
            "pub_year": 1999,
            "title": "A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability",
            "volume": "274"
        },
        "b0135": {
            "authors": [
                {
                    "first": "David T.",
                    "initial": "D.T.",
                    "last": "Shima"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Gougos"
                },
                {
                    "first": "Joan W.",
                    "initial": "J.W.",
                    "last": "Miller"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Tolentino"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Robinson"
                },
                {
                    "first": "Anthony P.",
                    "initial": "A.P.",
                    "last": "Adamis"
                },
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "D'Amore"
                }
            ],
            "firstpage": "1334",
            "issn": "01460404",
            "lastpage": "1340",
            "pmid": "8641836",
            "pub_year": 1996,
            "title": "Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis",
            "volume": "37"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Anne M.",
                    "initial": "A.M.",
                    "last": "Ryan"
                },
                {
                    "first": "Dorothy Bates",
                    "initial": "D.B.",
                    "last": "Eppler"
                },
                {
                    "first": "Kelly E.",
                    "initial": "K.E.",
                    "last": "Hagler"
                },
                {
                    "first": "Richard H.",
                    "initial": "R.H.",
                    "last": "Bruner"
                },
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Thomford"
                },
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Hall"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Shopp"
                },
                {
                    "first": "Charles A.",
                    "initial": "C.A.",
                    "last": "O'Neill"
                }
            ],
            "doi": "10.1177/019262339902700115",
            "firstpage": "78",
            "issn": "01926233",
            "lastpage": "86",
            "pmid": "10367678",
            "pub_year": 1999,
            "title": "Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody",
            "volume": "27"
        },
        "b0145": {
            "authors": [
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Gordon"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Margolin"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Talpaz"
                },
                {
                    "first": "Jr",
                    "initial": "J.",
                    "last": "Sledge"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Holmgren"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Benjamin"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Stalter"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Shak"
                },
                {
                    "first": "D. C.",
                    "initial": "D.C.",
                    "last": "Adelman"
                }
            ],
            "doi": "10.1200/JCO.2001.19.3.843",
            "firstpage": "843",
            "issn": "0732183X",
            "lastpage": "850",
            "pmid": "11157038",
            "pub_year": 2001,
            "title": "Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer",
            "volume": "19"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Henk M.W.",
                    "initial": "H.M.W.",
                    "last": "Verheul"
                },
                {
                    "first": "Martijn P.J.",
                    "initial": "M.P.J.",
                    "last": "Lolkema"
                },
                {
                    "first": "David Z.",
                    "initial": "D.Z.",
                    "last": "Qian"
                },
                {
                    "first": "Yvonne H.A.",
                    "initial": "Y.H.A.",
                    "last": "Hilkes"
                },
                {
                    "first": "Eleni",
                    "initial": "E.",
                    "last": "Liapi"
                },
                {
                    "first": "Jan Willem N.",
                    "initial": "J.W.N.",
                    "last": "Akkerman"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Pili"
                },
                {
                    "first": "Emile E.",
                    "initial": "E.E.",
                    "last": "Voest"
                }
            ],
            "doi": "10.1158/1078-0432.CCR-07-0847",
            "firstpage": "5341",
            "issn": "10780432",
            "lastpage": "5347",
            "pmid": "17855648",
            "pub_year": 2007,
            "title": "Platelets take up the monoclonal antibody bevacizumab",
            "volume": "13"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Christopher G.",
                    "initial": "C.G.",
                    "last": "Willett"
                },
                {
                    "first": "Dan G.",
                    "initial": "D.G.",
                    "last": "Duda"
                },
                {
                    "first": "Emmanuelle",
                    "initial": "E.",
                    "last": "Di Tomaso"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Boucher"
                },
                {
                    "first": "Marek",
                    "initial": "M.",
                    "last": "Ancukiewicz"
                },
                {
                    "first": "Dushyant V.",
                    "initial": "D.V.",
                    "last": "Sahani"
                },
                {
                    "first": "Johanna",
                    "initial": "J.",
                    "last": "Lahdenranta"
                },
                {
                    "first": "Daniel C.",
                    "initial": "D.C.",
                    "last": "Chung"
                },
                {
                    "first": "Alan J.",
                    "initial": "A.J.",
                    "last": "Fischman"
                },
                {
                    "first": "Gregory Y.",
                    "initial": "G.Y.",
                    "last": "Lauwers"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Shellito"
                },
                {
                    "first": "Brian G.",
                    "initial": "B.G.",
                    "last": "Czito"
                },
                {
                    "first": "Terence Z.",
                    "initial": "T.Z.",
                    "last": "Wong"
                },
                {
                    "first": "Erik",
                    "initial": "E.",
                    "last": "Paulson"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Poleski"
                },
                {
                    "first": "Zeljko",
                    "initial": "Z.",
                    "last": "Vujaskovic"
                },
                {
                    "first": "Rex",
                    "initial": "R.",
                    "last": "Bentley"
                },
                {
                    "first": "Helen X.",
                    "initial": "H.X.",
                    "last": "Chen"
                },
                {
                    "first": "Jeffrey W.",
                    "initial": "J.W.",
                    "last": "Clark"
                },
                {
                    "first": "Rakesh K.",
                    "initial": "R.K.",
                    "last": "Jain"
                }
            ],
            "doi": "10.1200/JCO.2008.21.1771",
            "firstpage": "3020",
            "issn": "0732183X",
            "lastpage": "3026",
            "pmid": "19470921",
            "pub_year": 2009,
            "title": "Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study",
            "volume": "27"
        }
    },
    "body_text": [
        {
            "endOffset": 45955,
            "parents": [],
            "secId": "s0095",
            "sentence": "Our study however is unique in its use of a fully synthetic 3D-structured peptide vaccine representing a truncated form of the functionally active subunit of hVEGF and shows that it is not required to use a fusion protein in order to break immune tolerance to a self-antigen.",
            "startOffset": 45680,
            "title": "Discussion"
        },
        {
            "endOffset": 35520,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "These findings were noted in all groups (Supplemental Table S5\u2013S6), however the incidence of these findings was considerably lower in group 3 (hVEGF26-104 only).",
            "startOffset": 35359,
            "title": "Pathology"
        },
        {
            "endOffset": 46983,
            "parents": [],
            "secId": "s0095",
            "sentence": "In sera in which antibodies were present (groups 4\u20137), hVEGF26-104 would immediately have been neutralized when entering the blood stream.",
            "startOffset": 46845,
            "title": "Discussion"
        },
        {
            "endOffset": 25706,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 25705,
                    "startOffset": 25698
                },
                "b0090": {
                    "endOffset": 25705,
                    "startOffset": 25698
                },
                "b0095": {
                    "endOffset": 25705,
                    "startOffset": 25698
                },
                "b0100": {
                    "endOffset": 25705,
                    "startOffset": 25698
                }
            },
            "secId": "s0005",
            "sentence": "In the first-in-human phase I clinical trial in patients with advanced solid tumors the vaccine was found to be safe and durable immune responses against VEGF were observed in 24 of 30 patients included [17\u201320].",
            "startOffset": 25495,
            "title": "Introduction"
        },
        {
            "endOffset": 26826,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Females were nulliparous and non-pregnant.",
            "startOffset": 26784,
            "title": "Animals"
        },
        {
            "endOffset": 36234,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "All animals survived to their scheduled necropsy.",
            "startOffset": 36185,
            "title": "Pathology"
        },
        {
            "endOffset": 37169,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "No anti-hVEGF165 antibodies were detected in any of the sera of group 3 (hVEGF26-104 only) showing the requirement of administering hVEGF26-104 together with RFASE adjuvant to induce anti-hVEGF165 antibodies.",
            "startOffset": 36961,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 29885,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Peripheral blood was examined in all animals for haematological, clinical chemistry, and coagulation parameters at baseline, at 24 hours and 42 days after the first immunization.",
            "startOffset": 29707,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 37501,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Titers of antibodies recognizing hVEGF26-104 on day 42 were found to be similar between the successfully immunized animals and groups (Supplemental Fig. S2).",
            "startOffset": 37344,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 29978,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "These measurements were repeated on day 70 for those animals included in the recovery study.",
            "startOffset": 29886,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 26783,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "At initiation of dosing, the monkeys were approximately 2 to 5 years of age and body weights ranged from 2.7 to 4.6 kg for males and 2.9 to 3.5 kg for females.",
            "startOffset": 26624,
            "title": "Animals"
        },
        {
            "endOffset": 46272,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 46271,
                    "startOffset": 46267
                }
            },
            "secId": "s0095",
            "sentence": "However, there are also reports describing counterintuitive increases in VEGF after bevacizumab treatment [31].",
            "startOffset": 46161,
            "title": "Discussion"
        },
        {
            "endOffset": 25331,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 25330,
                    "startOffset": 25326
                }
            },
            "secId": "s0005",
            "sentence": "In addition, VEGF inhibition through active immunization offers more effective neutralization since multiple epitopes of the VEGF protein are being targeted instead of only one epitope in the case of bevacizumab [10].",
            "startOffset": 25114,
            "title": "Introduction"
        },
        {
            "endOffset": 26376,
            "parents": [],
            "secId": "s0005",
            "sentence": "Furthermore, a potent neutralizing anti-VEGF antibody response could be induced.",
            "startOffset": 26296,
            "title": "Introduction"
        },
        {
            "endOffset": 45520,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 45519,
                    "startOffset": 45512
                },
                "b0080": {
                    "endOffset": 45519,
                    "startOffset": 45512
                }
            },
            "secId": "s0095",
            "sentence": "Earlier, the group of Gavilondo et al. published their successful VEGF vaccination strategies in non-human primates [15,16].",
            "startOffset": 45396,
            "title": "Discussion"
        },
        {
            "endOffset": 38796,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "No changes in serum hVEGF165 concentrations were observed in hVEGF26-104/RFASE immunized animals compared to group 1 (Fig. 4).",
            "startOffset": 38670,
            "title": "VEGF ELISA"
        },
        {
            "endOffset": 31483,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Detailed procedures on the bioassay are provided in the Supplementary Materials and Methods.",
            "startOffset": 31391,
            "title": "Ba/F3-VEGFR2 bioassay"
        },
        {
            "endOffset": 44261,
            "parents": [],
            "secId": "s0095",
            "sentence": "Interestingly, although these antisera proved to be active in the bioassay, the degree of cell proliferation inhibition did not correlate with the obtained anti-VEGF antibody titer, nor with the degree of competition with bevacizumab.",
            "startOffset": 44027,
            "title": "Discussion"
        },
        {
            "endOffset": 39811,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Nevertheless, the results do seem to indicate that immunization with hVEGF26-104/RFASE adjuvant (group 6) induced a low-level VEGF peptide specific type-1 T cell response, whereas no specific VEGF specific type-1 T cell responses were observed in any of the control groups (1, 2 and 3).",
            "startOffset": 39525,
            "title": "Determination of T cell response by IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 24602,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 24529,
                    "startOffset": 24524
                },
                "b0025": {
                    "endOffset": 24529,
                    "startOffset": 24524
                },
                "b0030": {
                    "endOffset": 24529,
                    "startOffset": 24524
                },
                "b0035": {
                    "endOffset": 24529,
                    "startOffset": 24524
                },
                "b0040": {
                    "endOffset": 24529,
                    "startOffset": 24524
                }
            },
            "secId": "s0005",
            "sentence": "It is suggested that tumor growth is still partially dependent on VEGF after disease progression on VEGF inhibition containing therapy [4\u20138], indicating differences in mechanism of resistance to anti-VEGF therapy.",
            "startOffset": 24389,
            "title": "Introduction"
        },
        {
            "endOffset": 32506,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "All data regarding group comparisons were analyzed using paired Student t-tests (in case of 2 groups) or one-way ANOVA (when comparing more than 2 groups).",
            "startOffset": 32351,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29423,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Body temperature was also recorded at approximately 168 hours post dose on day 29 to confirm the return to baseline levels over an extended period.",
            "startOffset": 29276,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 29155,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 29154,
                    "startOffset": 29150
                }
            },
            "secId": "s0030",
            "sentence": "Local injection site reactions were scored prior to each injection and 24 and 48 hours following each injection using the Draize scoring system [24].",
            "startOffset": 29006,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 41146,
            "parents": [],
            "secId": "s0095",
            "sentence": "This acute phase response was reversible, as no changes in these parameters compared to baseline were observed at the end of the dosing phase (day 42) or in the recovery study.",
            "startOffset": 40970,
            "title": "Discussion"
        },
        {
            "endOffset": 35754,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Furthermore, although there was no clear difference in incidence of the microscopic findings between the other groups, the severity of these microscopic findings appeared to be lower in group 1 (placebo) compared to the other groups.",
            "startOffset": 35521,
            "title": "Pathology"
        },
        {
            "endOffset": 26232,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here the safety and immunogenicity of hVEGF26-104 combined with RFASE adjuvant was investigated in a homologous model of human (cynomolgus monkeys).",
            "startOffset": 26084,
            "title": "Introduction"
        },
        {
            "endOffset": 38597,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "As depicted in Fig. 3D, antisera from groups 4, 5, 6 and 7 significantly inhibited VEGF driven cell proliferation in the Ba/F3-VEGFR2 bioassay, although this effect did not correlate with the anti-VEGF antibody titer or the inhibition of bevacizumab-hVEGF165 binding in the competition ELISA (data not shown).",
            "startOffset": 38288,
            "title": "VEGF neutralization in the Ba/F3-VEGFR2 bioassay"
        },
        {
            "endOffset": 44026,
            "parents": [],
            "secId": "s0095",
            "sentence": "Together, these results show the capacity of hVEGF26-104/RFASE vaccination to induce antibodies capable of blocking the binding of VEGF to VEGFR2 and to consequently inhibit the biological activity of hVEGF165.",
            "startOffset": 43816,
            "title": "Discussion"
        },
        {
            "endOffset": 34304,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The incidence as well as the menstrual cycle was not affected in groups 4\u20137 compared to the control groups (Supplemental Table S2), suggesting that hVEGF26-104/RFASE has no detrimental effects on physiological angiogenesis.",
            "startOffset": 34081,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 32021,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "After thawing a median cell yield of 14.4 \u2217 106 (calculated using a hemocytometer) was observed.",
            "startOffset": 31925,
            "title": "IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 36734,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "No other relevant microscopic findings were noted in any of the other organs from animals in the various test groups.",
            "startOffset": 36617,
            "title": "Pathology"
        },
        {
            "endOffset": 45396,
            "parents": [],
            "secId": "s0095",
            "sentence": "To test this hypothesis in future studies one could consider isolating immunoglobulins of all sera to diminish these potential non-specific effects.",
            "startOffset": 45248,
            "title": "Discussion"
        },
        {
            "endOffset": 26295,
            "parents": [],
            "secId": "s0005",
            "sentence": "We show that repeated immunization is safe and well tolerated.",
            "startOffset": 26233,
            "title": "Introduction"
        },
        {
            "endOffset": 27753,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "RFASE-adjuvant is a submicron emulsion of squalane-in-phosphate buffered saline (PBS) containing polysorbate 80 and RFASE (CML Europe BV, Weert, The Netherlands).",
            "startOffset": 27591,
            "title": "Vaccine"
        },
        {
            "endOffset": 35122,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Also no further changes were observed in the group of the recovery animals.",
            "startOffset": 35047,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 48036,
            "parents": [],
            "secId": "s0095",
            "sentence": "Collectively, our data show that hVEGF26-104/RFASE can be safely administered in cynomolgus monkeys at clinically relevant doses and that high titers of polyclonal anti-hVEGF antibodies can be induced with neutralizing abilities.",
            "startOffset": 47807,
            "title": "Discussion"
        },
        {
            "endOffset": 27590,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Raffinose Fatty Acid Sulphate Ester (RFASE) was synthesized by Amatsi (Saint Gely duFesc, France).",
            "startOffset": 27492,
            "title": "Vaccine"
        },
        {
            "endOffset": 27985,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "One mL of hVEGF26-104 was mixed with one mL RFASE adjuvant prior to administration.",
            "startOffset": 27902,
            "title": "Vaccine"
        },
        {
            "endOffset": 28892,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The animals scheduled for termination were sedated with ketamine and anesthetized by sodium pentobarbital.",
            "startOffset": 28786,
            "title": "Study design"
        },
        {
            "endOffset": 28247,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 28246,
                    "startOffset": 28242
                }
            },
            "secId": "s0025",
            "sentence": "The animals were assigned to 7 groups according to Fig. 1A. Different doses of antigen as well as adjuvant were selected based on extrapolation from previous rodent studies and on the anticipated dose to be used in the planned clinical trial [14].",
            "startOffset": 28000,
            "title": "Study design"
        },
        {
            "endOffset": 29568,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Blood pressure was measured once prior to hVEGF26-104/RFASE and at the end of the dosing period.",
            "startOffset": 29472,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 30577,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The Ba/F3-VEGFR2 cells were a kind gift from K. Alitalo (University of Helsinki, Finland) and were licensed by the Ludwig Institute for Cancer Research (New York, NY, USA).",
            "startOffset": 30405,
            "title": "Ba/F3-VEGFR2 bioassay"
        },
        {
            "endOffset": 33145,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The incidence and severity of edema as well as the incidence of muscle swelling increased after the booster immunizations (Table 1).",
            "startOffset": 33013,
            "title": "Injection site reactions and body temperature"
        },
        {
            "endOffset": 36960,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Induction of anti-hVEGF165 antibody responses was detected in all groups which received hVEGF26-104 together with RFASE adjuvant (groups 4, 5, 6 and 7) except for one animal in group 4 (Fig. 3A).",
            "startOffset": 36765,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 38965,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Unexpectedly, serum hVEGF concentrations measured in group 3 (animals vaccinated with hVEGF26-104 only) were significantly lower compared to control group 1 (p < 0.01).",
            "startOffset": 38797,
            "title": "VEGF ELISA"
        },
        {
            "endOffset": 46698,
            "parents": [],
            "secId": "s0095",
            "sentence": "A possible explanation for this observation could be that hVEGF26-104, administered 3 days earlier (day 43), had entered the blood stream and competed with hVEGF165 for binding with the capture antibody in the ELISA.",
            "startOffset": 46482,
            "title": "Discussion"
        },
        {
            "endOffset": 29639,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Blood was collected from all animals from a cephalic or saphenous vein.",
            "startOffset": 29568,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 42337,
            "parents": [],
            "secId": "s0095",
            "sentence": "In most of the animals of groups 4\u20137 high titers of cross-reactive anti-hVEGF165 antibodies were detected whereas this was not the case in groups 1\u20133.",
            "startOffset": 42187,
            "title": "Discussion"
        },
        {
            "endOffset": 28301,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Animals were immunized 4 times with 2 week intervals.",
            "startOffset": 28248,
            "title": "Study design"
        },
        {
            "endOffset": 39928,
            "parents": [],
            "secId": "s0095",
            "sentence": "This study evaluated the safety and immunogenicity of the hVEGF26-104/RFASE vaccine in cynomolgus monkeys.",
            "startOffset": 39822,
            "title": "Discussion"
        },
        {
            "endOffset": 38287,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "In a VEGF dependent bioassay (using Ba/F3-VEGFR2 cells) the VEGF neutralizing ability of all sera of groups 1, 4, 5, 6 and 7 were investigated.",
            "startOffset": 38144,
            "title": "VEGF neutralization in the Ba/F3-VEGFR2 bioassay"
        },
        {
            "endOffset": 43503,
            "parents": [],
            "secId": "s0095",
            "sentence": "Antisera from groups 4\u20137 were able to inhibit the binding of hVEGF165 to bevacizumab, indicating that the antibody responses induced by immunization comprised antibodies specific for the same VEGF epitope as bevacizumab.",
            "startOffset": 43283,
            "title": "Discussion"
        },
        {
            "endOffset": 44981,
            "parents": [],
            "secId": "s0095",
            "sentence": "Conversely, antisera which performed poorly in the competition ELISA could still have been very active in the Ba/F3-VEGFR2 bioassay because they might have contained antibodies that recognized discontinuous epitopes of native hVEGF but did not recognize linear and cryptic epitopes of hVEGF in the ELISA.",
            "startOffset": 44677,
            "title": "Discussion"
        },
        {
            "endOffset": 42528,
            "parents": [],
            "secId": "s0095",
            "sentence": "This clearly demonstrates the need for the truncated hVEGF26-104 vaccine to be administered together with an effective adjuvant in order to induce cross-reactive antibodies against hVEGF165.",
            "startOffset": 42338,
            "title": "Discussion"
        },
        {
            "endOffset": 40842,
            "parents": [],
            "secId": "s0095",
            "sentence": "In animals given hVEGF26-104 alone (group 3) there was only little modulation of these parameters, demonstrating adjuvant activity of RFASE.",
            "startOffset": 40702,
            "title": "Discussion"
        },
        {
            "endOffset": 44462,
            "parents": [],
            "secId": "s0095",
            "sentence": "This could be due to the fact that ELISA plate bound hVEGF could have become (partly) denaturated, whereas in the Ba/F3-VEGR2 bioassay hVEGF remains in solution and so should maintain its native form.",
            "startOffset": 44262,
            "title": "Discussion"
        },
        {
            "endOffset": 32231,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Cynomolgus PBMC were incubated with autologous monkey PMBC (which were pulsed with peptides derived of hVEGF165) for 10 days after which they were re-challenged with peptides and an IFN\u03b3 ELISPOT was performed.",
            "startOffset": 32022,
            "title": "IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 35046,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "All significant changes in haematological, chemical and coagulation parameters returned to baseline levels on day 42.",
            "startOffset": 34929,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 38669,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Serum hVEGF levels were measured at day 46 for all animals.",
            "startOffset": 38610,
            "title": "VEGF ELISA"
        },
        {
            "endOffset": 33446,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In animals which received RFASE adjuvant alone (group 2) or in combination with hVEGF26-104 (groups 4, 5, 6 and 7) a mild increase in body temperature was observed after all immunizations (mean \u00b1 SD; 0.53 \u00b0C \u00b1 0.15 \u00b0C, 24 hours after third immunization) (Fig. 2A for changes after third immunization).",
            "startOffset": 33145,
            "title": "Injection site reactions and body temperature"
        },
        {
            "endOffset": 32828,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Findings were considered statistically significant when p-values were \u2264 0.05, as indicated with asterisks (*p \u2264 0.05, **p \u2264 0.01, ***p \u2264 0.001).",
            "startOffset": 32684,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 25851,
            "parents": [],
            "secId": "s0005",
            "sentence": "hVEGF26-104/RFASE is a therapeutic anti-angiogenic vaccine aimed at inducing a cross-reactive polyclonal antibody response against human VEGF165.",
            "startOffset": 25706,
            "title": "Introduction"
        },
        {
            "endOffset": 46844,
            "parents": [],
            "secId": "s0095",
            "sentence": "As the detection antibody is not able to bind this monomeric molecule, this would have resulted in lower detectable levels of VEGF165 in group 3.",
            "startOffset": 46699,
            "title": "Discussion"
        },
        {
            "endOffset": 40466,
            "parents": [],
            "secId": "s0095",
            "sentence": "This study demonstrated that immunization is safe and well tolerated.",
            "startOffset": 40397,
            "title": "Discussion"
        },
        {
            "endOffset": 28729,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Twelve animals (4 animals each of groups 1, 6 and 7) were included in the recovery study to evaluate reversibility of toxicity and immunogenicity of this vaccine for another 4 weeks following the fourth immunization (Fig. 1B).",
            "startOffset": 28503,
            "title": "Study design"
        },
        {
            "endOffset": 45679,
            "parents": [],
            "secId": "s0095",
            "sentence": "Our results have thus confirmed their findings that it is possible to induce high titers of anti-VEGF antibodies through active immunization in these species.",
            "startOffset": 45521,
            "title": "Discussion"
        },
        {
            "endOffset": 25420,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 25419,
                    "startOffset": 25412
                },
                "b0060": {
                    "endOffset": 25419,
                    "startOffset": 25412
                },
                "b0065": {
                    "endOffset": 25419,
                    "startOffset": 25412
                },
                "b0070": {
                    "endOffset": 25419,
                    "startOffset": 25412
                }
            },
            "secId": "s0005",
            "sentence": "Our group and others have already investigated the potential of VEGF vaccination [11\u201314].",
            "startOffset": 25331,
            "title": "Introduction"
        },
        {
            "endOffset": 32328,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Detailed procedures on the IFN\u03b3 ELISPOT are provided in the Supplementary Materials and Methods.",
            "startOffset": 32232,
            "title": "IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 33811,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The increase in body temperature 24 hours after immunization did not differ significantly between groups 5, 6 and 7, however the increase in body temperature in group 4 was significantly larger compared to group 6 (0.77 \u00b1 0.46 \u00b0C in group 4 versus 0.34 \u00b1 0.46 \u00b0C in group 6; p < 0.05).",
            "startOffset": 33526,
            "title": "Injection site reactions and body temperature"
        },
        {
            "endOffset": 39524,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "According to our definition for positive reactivity (see Supplementary Materials and Methods) none of the tested samples showed significant positive reactivity against hVEGF, since there was a high background value in the control samples (DMSO only).",
            "startOffset": 39274,
            "title": "Determination of T cell response by IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 47454,
            "parents": [],
            "secId": "s0095",
            "sentence": "Due to the low number of lymphocytes after thawing, these experiments were only possible in 16/24 animals.",
            "startOffset": 47348,
            "title": "Discussion"
        },
        {
            "endOffset": 25005,
            "parents": [],
            "secId": "s0005",
            "sentence": "Targeting VEGF by active immunization has the advantage that it offers sustained and stable VEGF suppression.",
            "startOffset": 24896,
            "title": "Introduction"
        },
        {
            "endOffset": 42985,
            "parents": [],
            "secId": "s0095",
            "sentence": "No clear differences were observed in the kinetics of antibody induction between groups 4 and 7, suggesting that the lowest antigen dose used in the study is still well above the threshold for breaking immune tolerance and induction of humoral immunity.",
            "startOffset": 42732,
            "title": "Discussion"
        },
        {
            "endOffset": 44676,
            "parents": [],
            "secId": "s0095",
            "sentence": "Antisera that recognize linear and cryptic epitopes of hVEGF in ELISA might not have recognized discontinuous binding epitopes of native hVEGF and might therefore have performed worse in the Ba/F3-VEGFR2 bioassay.",
            "startOffset": 44463,
            "title": "Discussion"
        },
        {
            "endOffset": 33012,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Edema and muscle swelling were mainly observed in groups which received RFASE adjuvant alone or in combination with hVEGF26-104.",
            "startOffset": 32884,
            "title": "Injection site reactions and body temperature"
        },
        {
            "endOffset": 36185,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "In the recovery group the incidence and severity of these microscopic findings was decreased on day 70 (Supplemental Table S7\u2013S8).",
            "startOffset": 36055,
            "title": "Pathology"
        },
        {
            "endOffset": 36493,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "One animal of group 6 had moderate degeneration of the seminiferous tubules.",
            "startOffset": 36417,
            "title": "Pathology"
        },
        {
            "endOffset": 30381,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Detailed procedures on the determination of anti-VEGF antibodies and competition ELISAs are provided in the Supplementary Materials and Methods.",
            "startOffset": 30237,
            "title": "ELISA"
        },
        {
            "endOffset": 43815,
            "parents": [],
            "secId": "s0095",
            "sentence": "Most of the antisera of groups 4\u20137 inhibited the proliferation of Ba/F3-VEGFR2 cells when co-incubated with hVEGF165.",
            "startOffset": 43698,
            "title": "Discussion"
        },
        {
            "endOffset": 34928,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In these groups activated partial thromboplastin time (APTT) and fibrinogen were also increased on day 2 compared to group 1 (Supplemental Table S4).",
            "startOffset": 34779,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 43282,
            "parents": [],
            "secId": "s0095",
            "sentence": "The ability of these antibodies to block the biological activity of VEGF was assessed in a competition ELISA with bevacizumab and in the Ba/F3-VEGFR2 bioassay.",
            "startOffset": 43123,
            "title": "Discussion"
        },
        {
            "endOffset": 40701,
            "parents": [],
            "secId": "s0095",
            "sentence": "Relatively mild signs of acute phase reactions, like local injection site reactions, increases in body temperature, CRP and WBC, were observed in all animals receiving RFASE adjuvant alone or together with hVEGF26-104 (groups 2, 4\u20137).",
            "startOffset": 40467,
            "title": "Discussion"
        },
        {
            "endOffset": 29706,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Animals were fasted overnight prior to blood and urine collection.",
            "startOffset": 29640,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 47347,
            "parents": [],
            "secId": "s0095",
            "sentence": "An attempt to identify possible cellular immunity to VEGF after immunization was done by performing IFN\u03b3 ELISPOT assays with PBMCs isolated from animals of groups 1, 2, 3 and 6 and peptide pools derived of hVEGF165.",
            "startOffset": 47132,
            "title": "Discussion"
        },
        {
            "endOffset": 47492,
            "parents": [],
            "secId": "s0095",
            "sentence": "Overall, the reactivity was very low.",
            "startOffset": 47455,
            "title": "Discussion"
        },
        {
            "endOffset": 28387,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The monkeys were immunized by 2 intramuscular injections in the left and right thigh.",
            "startOffset": 28302,
            "title": "Study design"
        },
        {
            "endOffset": 29471,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Body weight of each animal was recorded weekly.",
            "startOffset": 29424,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 27901,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 27900,
                    "startOffset": 27893
                },
                "b0115": {
                    "endOffset": 27900,
                    "startOffset": 27893
                }
            },
            "secId": "s0020",
            "sentence": "RFASE adjuvant is designed to work as an antigen depot, to be immune stimulating, and to skew the immune response towards humoral immunity [14,23].",
            "startOffset": 27754,
            "title": "Vaccine"
        },
        {
            "endOffset": 40969,
            "parents": [],
            "secId": "s0095",
            "sentence": "The antigen dosage of hVEGF26-104 and dose of RFASE adjuvant did not affect the severity of the observed acute phase reaction.",
            "startOffset": 40843,
            "title": "Discussion"
        },
        {
            "endOffset": 27108,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 27107,
                    "startOffset": 27103
                }
            },
            "secId": "s0020",
            "sentence": "The synthesis of the truncated peptide hVEGF26-104 is described elsewhere [14].",
            "startOffset": 27029,
            "title": "Vaccine"
        },
        {
            "endOffset": 26623,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The animals were purchased at Hainan Jingang Biotech Co., Ltd. (Nayang Xintan, Fucheng, Qiongshan District, Haikou, Hainan Province, China).",
            "startOffset": 26483,
            "title": "Animals"
        },
        {
            "endOffset": 26482,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Fifty-four male and female (n = 27 for each) cynomolgus monkeys were used in this study.",
            "startOffset": 26394,
            "title": "Animals"
        },
        {
            "endOffset": 42187,
            "parents": [],
            "secId": "s0095",
            "sentence": "This difference in toxicity between monoclonal antibody therapy and active immunization could derive from the fact that immunization provides a delayed and rather stable antibody titer without an acute early peak in antibody concentration, as is the case upon bevacizumab administration.",
            "startOffset": 41900,
            "title": "Discussion"
        },
        {
            "endOffset": 41899,
            "parents": [],
            "secId": "s0095",
            "sentence": "Nevertheless, one should remain cautious of anti VEGF-related adverse events during clinical development of a therapeutic vaccine targeting VEGF.",
            "startOffset": 41754,
            "title": "Discussion"
        },
        {
            "endOffset": 29275,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Body temperature was recorded from all animals prior to each injection and 3, 24, 48 and 96 hours after the injections.",
            "startOffset": 29156,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 37941,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "As depicted in Fig. 3B, antisera induced by hVEGF26-104/RFASE immunization were able to inhibit the binding of hVEGF165 to bevacizumab, indicating that the antibody responses induced by immunization comprised antibodies that target the same hVEGF165 epitope as bevacizumab.",
            "startOffset": 37668,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 35358,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Microscopic findings at the intramuscular injection sites included minimal to moderate interstitial fibroplasia and infiltrates with foamy macrophages as well as minimal to mild eosinophilic and mononuclear cell infiltrates.",
            "startOffset": 35134,
            "title": "Pathology"
        },
        {
            "endOffset": 33525,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "After 48 hours the body temperature in all groups returned to baseline levels.",
            "startOffset": 33447,
            "title": "Injection site reactions and body temperature"
        },
        {
            "endOffset": 25980,
            "parents": [],
            "secId": "s0005",
            "sentence": "Through minor modifications in the amino acid sequence and truncation of the hVEGF protein, immune self-tolerance can be broken.",
            "startOffset": 25852,
            "title": "Introduction"
        },
        {
            "endOffset": 36416,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Necropsy revealed that there were no RFASE or hVEGF26-104 vaccine-related organ weight changes at either day 46 (main study) or day 70 (recovery study) (Supplemental Tables S9\u2013S10).",
            "startOffset": 36235,
            "title": "Pathology"
        },
        {
            "endOffset": 39273,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "To determine whether immunization with hVEGF26-104/RFASE also induced a type-1 T cell response against hVEGF, an IFN\u03b3 ELISPOT assay was performed on PBMCs isolated from 12 randomly selected animals from groups 1, 2, 3 and 6 at day 46 (Supplemental Fig. S3).",
            "startOffset": 39016,
            "title": "Determination of T cell response by IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 24388,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 24342,
                    "startOffset": 24337
                },
                "b0010": {
                    "endOffset": 24342,
                    "startOffset": 24337
                },
                "b0015": {
                    "endOffset": 24342,
                    "startOffset": 24337
                }
            },
            "secId": "s0005",
            "sentence": "Targeting VEGF with the monoclonal antibody bevacizumab or the fusion protein aflibercept prolongs the survival of advanced cancer patients [1\u20133] when administered together with chemotherapy.",
            "startOffset": 24197,
            "title": "Introduction"
        },
        {
            "endOffset": 40121,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 40029,
                    "startOffset": 40025
                }
            },
            "secId": "s0095",
            "sentence": "Given the fact that the protein sequence of cynomolgus VEGF is homologous to that of human VEGF [27], this species provided an ideal model to study the immunological properties of the vaccine.",
            "startOffset": 39929,
            "title": "Discussion"
        },
        {
            "endOffset": 31138,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "In brief, parental Ba/F3 cells were transfected with a receptor chimera consisting of the extracellular domain of VEGFR2 and the transmembrane and cytoplasmic domain of mouse erythropoietin receptor (mEpoR), resulting in a cell line which is dependent on human VEGF (hVEGF; R&D systems, Minneapolis, USA) or mouse IL-3 (mIL3; R&D systems, Minneapolis, USA) for proliferation and survival.",
            "startOffset": 30750,
            "title": "Ba/F3-VEGFR2 bioassay"
        },
        {
            "endOffset": 33963,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Body weights (Supplemental Fig. S1) and food consumption (data not shown) were well maintained during the study.",
            "startOffset": 33851,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 26084,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 26083,
                    "startOffset": 26079
                }
            },
            "secId": "s0005",
            "sentence": "Its in vivo VEGF neutralizing and tumor suppressive abilities were already shown by us previously [14].",
            "startOffset": 25981,
            "title": "Introduction"
        },
        {
            "endOffset": 37257,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Peak anti-hVEGF165 antibody titers were reached 6\u20138 weeks after the first immunization.",
            "startOffset": 37170,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 29005,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The animals were checked twice daily for signs of morbidity or mortality.",
            "startOffset": 28932,
            "title": "Physical and biochemical examinations"
        },
        {
            "endOffset": 41584,
            "parents": [],
            "secId": "s0095",
            "sentence": "Of note, no adverse events associated with VEGF neutralization (such as hypertension or ovarian failure) were observed in any of the animals (Supplemental Table S1\u20132).",
            "startOffset": 41417,
            "title": "Discussion"
        },
        {
            "endOffset": 34080,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Immunization with hVEGF26-104/RFASE was not associated with the development of hypertension (Supplemental Table S1).",
            "startOffset": 33964,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 30236,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Serum hVEGF concentrations were measured for all animals in the main study at day 46 using a commercially available enzyme-linked immunosorbent assay (ELISA) (Quantikine, R&D Systems Europe, Abingdon, UK) according to the manufacturers\u2019 instructions.",
            "startOffset": 29986,
            "title": "ELISA"
        },
        {
            "endOffset": 40397,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 40396,
                    "startOffset": 40392
                }
            },
            "secId": "s0095",
            "sentence": "The peptide hVEGF26-104 perfectly resembles the 3D structure of the bevacizumab binding epitope on hVEGF165 and ensures the induction of highly neutralizing cross-reactive antibodies since they recognize discontinuous epitopes on hVEGF165 important for receptor binding [14].",
            "startOffset": 40122,
            "title": "Discussion"
        },
        {
            "endOffset": 47132,
            "parents": [],
            "secId": "s0095",
            "sentence": "As a result the actual VEGF165 concentrations measured in this sandwich ELISA could have remained unaffected or could even have been underestimated.",
            "startOffset": 46984,
            "title": "Discussion"
        },
        {
            "endOffset": 47679,
            "parents": [],
            "secId": "s0095",
            "sentence": "However, it is notable that relatively higher reactivity was observed in group 6, suggestive of a (weak) type-1 T cell immune response being induced by the hVEGF26-104/RFASE combination.",
            "startOffset": 47493,
            "title": "Discussion"
        },
        {
            "endOffset": 48187,
            "parents": [],
            "secId": "s0095",
            "sentence": "A first-in-human phase I clinical trial has started to investigate the safety and immunogenicity in patients with advanced solid tumors (NCT02237638).",
            "startOffset": 48037,
            "title": "Discussion"
        },
        {
            "endOffset": 24896,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 24895,
                    "startOffset": 24892
                }
            },
            "secId": "s0005",
            "sentence": "However, the clinical benefit achieved with these agents remains fairly modest, stressing the need to find ways to enhance the therapeutic effect of drugs targeting VEGF, especially since it has been suggested that long-term VEGF inhibition is required to maximize the therapeutic benefit [9].",
            "startOffset": 24603,
            "title": "Introduction"
        },
        {
            "endOffset": 25494,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 25493,
                    "startOffset": 25486
                },
                "b0080": {
                    "endOffset": 25493,
                    "startOffset": 25486
                }
            },
            "secId": "s0005",
            "sentence": "Gavilondo et al. developed the therapeutic VEGF vaccine CIGB-247 [15,16].",
            "startOffset": 25421,
            "title": "Introduction"
        },
        {
            "endOffset": 36616,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Because this change only occurred in one animal, it remained uncertain if these changes were related to hVEGF26-104/RFASE.",
            "startOffset": 36494,
            "title": "Pathology"
        },
        {
            "endOffset": 30749,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 30748,
                    "startOffset": 30741
                },
                "b0130": {
                    "endOffset": 30748,
                    "startOffset": 30741
                }
            },
            "secId": "s0040",
            "sentence": "The parental cell line is a murine interleukin-3 dependent pre-B lymphocyte cell line; the development of the Ba/F3 cells expressing VEGFR2 is described elsewhere [25,26].",
            "startOffset": 30578,
            "title": "Ba/F3-VEGFR2 bioassay"
        },
        {
            "endOffset": 45247,
            "parents": [],
            "secId": "s0095",
            "sentence": "Although non-immune sera were found to have little effect on Ba/F3-VEGFR2 cell proliferation (group 1), it is possible that sera of group 2 (adjuvant only) might reveal non-specific background neutralization, because of non-specific activation of the immune system.",
            "startOffset": 44982,
            "title": "Discussion"
        },
        {
            "endOffset": 38093,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Moreover, the anti-VEGF antibody titers positively correlated with the percentage of inhibition of bevacizumab-hVEGF165 binding (p < 0.0001) (Fig. 3C).",
            "startOffset": 37942,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 41416,
            "parents": [],
            "secId": "s0095",
            "sentence": "Although no blood was drawn for the purpose of hematology, chemistry and coagulation parameters 24 hours after booster immunizations, similar levels of WBC as well as CRP at baseline and day 42 indicate that study animals did not permanently adapt to the interventions.",
            "startOffset": 41147,
            "title": "Discussion"
        },
        {
            "endOffset": 46481,
            "parents": [],
            "secId": "s0095",
            "sentence": "Intriguingly, in this study no changes in VEGF levels were observed on day 46 in groups 4\u20137, as compared to group 1, whereas the serum VEGF concentration in group 3 (hVEGF26-104 only) was significantly lower.",
            "startOffset": 46273,
            "title": "Discussion"
        },
        {
            "endOffset": 37343,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Peak antibody titers varied between 1.5 and 4.3 (serum dilutions of 1:31 to 1:19953).",
            "startOffset": 37258,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 46160,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 46079,
                    "startOffset": 46075
                },
                "b0150": {
                    "endOffset": 46159,
                    "startOffset": 46155
                }
            },
            "secId": "s0095",
            "sentence": "When patients are treated with bevacizumab, serum VEGF levels often seem profoundly decreased after one treatment cycle [29], because VEGF bound to bevacizumab is not recognized in the R&D VEGF ELISA [30].",
            "startOffset": 45955,
            "title": "Discussion"
        },
        {
            "endOffset": 43123,
            "parents": [],
            "secId": "s0095",
            "sentence": "However the data do seem to indicate that a lower antigen dose (group 4) is associated with a delayed induction of anti-hVEGF antibodies.",
            "startOffset": 42986,
            "title": "Discussion"
        },
        {
            "endOffset": 32683,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "For the analysis of the correlation of anti-VEGF antibody titers and the percentage of inhibition of bevacizumab-hVEGF165 binding, the Pearson correlation coefficient was used.",
            "startOffset": 32507,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 25113,
            "parents": [],
            "secId": "s0005",
            "sentence": "This means that treatment would be less burdensome for patients, while the cost-effectiveness is increased.",
            "startOffset": 25006,
            "title": "Introduction"
        },
        {
            "endOffset": 28785,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A complete necropsy was conducted on all study animals.",
            "startOffset": 28730,
            "title": "Study design"
        },
        {
            "endOffset": 34574,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Significant increases in white blood cell (WBC) count (p < 0.05) and C reactive protein (CRP) (p < 0.05) on day 2, as compared to baseline were observed in animals that received RFASE adjuvant alone or in combination with hVEGF26-104 (groups 2, 4, 5, 6 and 7) (Fig. 2B).",
            "startOffset": 34304,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 27336,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 27335,
                    "startOffset": 27331
                }
            },
            "secId": "s0020",
            "sentence": "In addition to truncation of the endogenous protein (hVEGF165) to 79 amino acids (26\u2013104), 2 cysteines on residues 51 and 60 were replaced by alanines to prevent dimerization of the protein and consequent receptor binding [21].",
            "startOffset": 27109,
            "title": "Vaccine"
        },
        {
            "endOffset": 41753,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 41706,
                    "startOffset": 41702
                }
            },
            "secId": "s0095",
            "sentence": "As bevacizumab administration was associated with more anti-VEGF related adverse events in cynomolgus monkey studies [28], this observation is particularly encouraging.",
            "startOffset": 41585,
            "title": "Discussion"
        },
        {
            "endOffset": 31390,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The neutralizing abilities of vaccination-induced antibodies were assessed by a Ba/F3-VEGFR2 cell proliferation assay in which animals\u2019 sera (10% of serum collected on day 46 of the study) were co-incubated with hVEGF 1.25 ng/mL and Ba/F3-VEGFR2 cells.",
            "startOffset": 31138,
            "title": "Ba/F3-VEGFR2 bioassay"
        },
        {
            "endOffset": 27492,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 27491,
                    "startOffset": 27487
                }
            },
            "secId": "s0020",
            "sentence": "The peptide was purified by HPLC and correctly folded to form the cys-knot structure of VEGF according to the folding conditions as described earlier [22].",
            "startOffset": 27337,
            "title": "Vaccine"
        },
        {
            "endOffset": 31686,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The ability of hVEGF26-104/RFASE to induce a VEGF specific cytotoxic T cell (CTL) response was assessed using a commercially available primate IFN\u03b3 ELISpot (MabTech, Nacka Strand, Sweden).",
            "startOffset": 31498,
            "title": "IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 28502,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Three days after the fourth immunization (day 46) animals were euthanized for the determination of organ toxicity.",
            "startOffset": 28388,
            "title": "Study design"
        },
        {
            "endOffset": 27019,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study plan and any amendments or procedures involving the care or use of animals on this study was reviewed and approved by WuXi AppTec Institutional Animal Care and Use Committee (IACUC).",
            "startOffset": 26827,
            "title": "Animals"
        },
        {
            "endOffset": 31924,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Peripheral Blood Mononuclear Cells (PBMC) were isolated from EDTA blood by density gradient centrifugation using Lymphoprep (Axis-Shield PoC AS, Osly, Norway) and cryopreserved in freezing medium (87.5% FCS/12.5% DMSO) until further use.",
            "startOffset": 31687,
            "title": "IFN\u03b3 ELISPOT"
        },
        {
            "endOffset": 37667,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "All sera of groups 4, 5, 6 and 7 were tested in a competition ELISA to evaluate whether these sera, were able to compete with bevacizumab for the binding to hVEGF165.",
            "startOffset": 37501,
            "title": "Anti-VEGF antibody responses"
        },
        {
            "endOffset": 34778,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The increase in WBC count was largely due to increased neutrophils (both absolute counts and percentages), whereas lymphocytes decreased (both counts and percentages) (Fig. 2C and Supplemental Table S3).",
            "startOffset": 34575,
            "title": "Physical and biochemical observations"
        },
        {
            "endOffset": 42731,
            "parents": [],
            "secId": "s0095",
            "sentence": "Of note, the apparent low-efficiency priming of a type-1 T cell response suggests the particular suitability of the RFASE adjuvant for the priming of the type-2 T cells and subsequent humoral responses.",
            "startOffset": 42529,
            "title": "Discussion"
        },
        {
            "endOffset": 36054,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Finally, the finding of mononuclear cell infiltrates appeared to be correlated with the induction of antibodies since the incidence and severity of these infiltrates were higher in those groups that received hVEGF26-104 together with RFASE adjuvant (groups 4, 5, 6 and 7) (Supplemental Table S5\u2013S6).",
            "startOffset": 35755,
            "title": "Pathology"
        },
        {
            "endOffset": 47807,
            "parents": [],
            "secId": "s0095",
            "sentence": "Future research should elucidate whether hVEGF26-104/RFASE indeed is able to induce cellular immunity next to humoral immunity.",
            "startOffset": 47680,
            "title": "Discussion"
        },
        {
            "endOffset": 43697,
            "parents": [],
            "secId": "s0095",
            "sentence": "Results suggested that antisera of group 4 had a lower ability to inhibit the binding of bevacizumab to hVEGF compared to groups 5\u20137, although this difference was not statistically significant.",
            "startOffset": 43504,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X18302536",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Madelon Q.",
                "initial": "M.Q.",
                "last": "Wentink"
            },
            {
                "email": null,
                "first": "Henk M.W.",
                "initial": "H.M.W.",
                "last": "Verheul"
            },
            {
                "email": null,
                "first": "Arjan W.",
                "initial": "A.W.",
                "last": "Griffioen"
            },
            {
                "email": null,
                "first": "Kenneth A.",
                "initial": "K.A.",
                "last": "Schafer"
            },
            {
                "email": null,
                "first": "Susan",
                "initial": "S.",
                "last": "McPherson"
            },
            {
                "email": null,
                "first": "Richard J.",
                "initial": "R.J.",
                "last": "Early"
            },
            {
                "email": null,
                "first": "Hans J.",
                "initial": "H.J.",
                "last": "van der Vliet"
            },
            {
                "email": "td.degruijl@vumc.nl",
                "first": "Tanja D.",
                "initial": "T.D.",
                "last": "de Gruijl"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.02.066",
        "firstpage": "2025",
        "issn": "0264410X",
        "keywords": [
            "Angiogenesis",
            "Antibodies",
            "Cynomolgus monkeys",
            "VEGF",
            "Vaccine"
        ],
        "lastpage": "2032",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys"
    }
}